Please assess the completion status of the following clinical trial:

Trial Title: Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant, non lactating females 18 years of age or older.~2. Signed informed consent form, which meets all criteria of current FDA regulations and the requirements of the India regulatory authorities.~3. If female and of child bearing potential, have a negative urine pregnancy test at the baseline visit,~4. A total score of at least six (6) for the following eight (8) clinical signs and symptoms of interdigital tinea pedis: fissuring, erythema, maceration, vesiculation, desquamation/scaling, exudation, pruritus, burning/stinging. In addition the most infected area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for either pruritus or desquamation/scaling~5. A confirmed clinical diagnosis of interdigital tinea pedis.~6. The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination (potassium hydroxide mount preparation).~7. Identification of an appropriate dermatophyte by culture sent to the central laboratory. The appropriate dermatophytes are Trichophyton rubrum, Trichophyton mentagrophytes or Epidermophyton floccosum.~Exclusion Criteria:~1. Use of any of the following within the indicated timeline:~   * Oral or injectable steroids within four weeks of the study start.~  * Any oral anti-fungals within 4 weeks of the study start.~  * Use of topical corticosteroids or any other topical antipruritics on the feet within 72 hours of the study start.~  * Any prescription or OTC topical antifungal on the feet within two weeks prior to study entry.~  * Use of any antihistamines within 72 hours of the study start.~2. Any known hypersensitivity to butenafine or other antifungal agents.~3. Evidence of any concurrent dermatophytic infection of toe nails (onychomycosis) or other dermatological condition of the foot that may interfere with the Investigators evaluation of tinea pedis.~4. Patients with recurrent tinea pedis (more than 3 infections in the past 12 months) who have been unresponsive to previous antifungal therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Butenafine Hydrochloride 1% A (Type: EXPERIMENTAL): 1
- Butenafine Hydrochloride 1% B (Type: EXPERIMENTAL): 2
- Butenafine Hydrochloride 1% (Type: ACTIVE_COMPARATOR): 3
- Vehicle A (Type: PLACEBO_COMPARATOR): 4
- Vehicle B (Type: PLACEBO_COMPARATOR): 5

Based on this trial design, predict the completion outcome and termination type (if applicable).